X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
prostate cancer (13) 13
humans (12) 12
aged (11) 11
index medicus (11) 11
male (11) 11
oncology (9) 9
hematology, oncology and palliative medicine (8) 8
metastasis (8) 8
aged, 80 and over (7) 7
disease progression (7) 7
cancer (6) 6
cancer therapies (6) 6
care and treatment (6) 6
chemotherapy (6) 6
docetaxel (6) 6
increased survival (6) 6
men (6) 6
prognosis (6) 6
prostatic neoplasms, castration-resistant - drug therapy (6) 6
prostatic neoplasms, castration-resistant - pathology (6) 6
abiraterone acetate (5) 5
bone neoplasms - secondary (5) 5
double-blind method (5) 5
pain (5) 5
prednisone (5) 5
treatment outcome (5) 5
adult (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
corticosteroids (4) 4
disease-free survival (4) 4
double-blind (4) 4
middle aged (4) 4
mitoxantrone (4) 4
prostatic neoplasms - pathology (4) 4
prostatic neoplasms, castration-resistant - mortality (4) 4
analysis (3) 3
bone neoplasms - drug therapy (3) 3
business & economics (3) 3
clinical trials (3) 3
complications (3) 3
electronic books (3) 3
enzalutamide (3) 3
follow-up studies (3) 3
hospitals (3) 3
kaplan-meier estimate (3) 3
medical colleges (3) 3
neoplasm metastasis (3) 3
neoplasm staging (3) 3
plus prednisone (3) 3
political science (3) 3
prostate-specific antigen - blood (3) 3
prostatic neoplasms - mortality (3) 3
survival (3) 3
survival analysis (3) 3
survival rate (3) 3
zoledronic acid (3) 3
androgens (2) 2
antigens (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bone cancer (2) 2
bone metastases (2) 2
castration (2) 2
cells (2) 2
development and progression (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
drug therapy (2) 2
economía marxista (2) 2
health aspects (2) 2
marxian economics (2) 2
medical prognosis (2) 2
medical treatment (2) 2
mitoxantrone plus prednisone (2) 2
mortality (2) 2
neoplasm grading (2) 2
neoplasm recurrence, local - drug therapy (2) 2
orchiectomy (2) 2
placebo-controlled phase-3 (2) 2
practice guidelines as topic (2) 2
prednisone - administration & dosage (2) 2
product development (2) 2
prostatic neoplasms - drug therapy (2) 2
radioisotopes - therapeutic use (2) 2
radium - therapeutic use (2) 2
research (2) 2
risk factors (2) 2
steroids (2) 2
taxoids - administration & dosage (2) 2
urology & nephrology (2) 2
1818-1883 (1) 1
1945 (1) 1
abiraterone (1) 1
abridged index medicus (1) 1
acts of terrorism (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - enzymology (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
administration, oral (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9810, pp. 39 - 46
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1307 - 1316
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 473 - 485
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1263 - 1268
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 338 - 348
Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | ONCOLOGY | MEN | END-POINTS | ABIRATERONE ACETATE | INCREASED SURVIVAL | DOCETAXEL | ENZALUTAMIDE | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | North America | Prostatic Neoplasms, Castration-Resistant - pathology | Time Factors | Prednisone - administration & dosage | Double-Blind Method | Europe | Risk Factors | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Adenocarcinoma - secondary | Disease Progression | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Naphthalenes - administration & dosage | Intention to Treat Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Australia | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Cytochrome P-450 | Clinical trials | Prednisone | Metastasis | Prostate cancer | Cancer | Steroids
Journal Article
European Medical Journal Urology, 05/2015, Volume 3, Issue 2, pp. 57 - 62
The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate... 
EAU Congress | Annual European Association of Urology Congress
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. e404 - e414
Journal Article